keyword
MENU ▼
Read by QxMD icon Read
search

bioresorbable

keyword
https://www.readbyqxmd.com/read/28922543/in-vitro-and-in-vivo-degradation-of-microfiber-bioresorbable-coronary-scaffold
#1
Chi-Hung Huang, Sheng-Yang Lee, Sonida Horng, Louis-Georges Guy, Ting-Bin Yu
The degradation of Mirage Bioresorbable Microfiber Scaffold was evaluated in vitro and in vivo. The degradation in polymer molecular weight (MW), strut morphology, and integrity was accessed using gel permeation chromatography (GPC), X-ray micro-computed tomography (micro-CT) evaluation. To simulate the physiological degradation in vitro, scaffolds were deployed in silicone mock vessels connected to a peristaltic pumping system, which pumps 37°C phosphate-buffered saline (PBS, pH 7.4) at a constant rate. At various time points (30D, 60D, 90D, 180D, 270D, and 360D), the MW of microfibers decreased to 57...
September 18, 2017: Journal of Biomedical Materials Research. Part B, Applied Biomaterials
https://www.readbyqxmd.com/read/28921952/nano-air-seeds-trapped-in-mesoporous-janus-nanoparticles-facilitate-cavitation-and-enhance-ultrasound-imaging
#2
Konstantin Tamarov, Andrey Sviridov, Wujun Xu, Markus Malo, Valery Andreev, Victor Yu Timoshenko, Vesa-Pekka Lehto
The current contrast agents utilized in ultrasound (US) imaging are based on microbubbles which, however, suffer from a short lifetime in the systemic circulation. The present study introduces a new type of contrast agents for US imaging based on bioresorbable Janus nanoparticles (NPs) that are able to generate microbubbles in situ under US radiation for extended time. The Janus NPs were fabricated from porous silicon (PSi) that was modified via a nanostopper technique. The technique was exploited to prepare PSi NPs which had hydrophobic pore walls (inner face) while the external surfaces of the NPs (outer face) were hydrophilic...
September 18, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28916979/ventral-hernia-repair-with-poly-4-hydroxybutyrate-mesh
#3
Margaret A Plymale, Daniel L Davenport, Adam Dugan, Amanda Zachem, John Scott Roth
BACKGROUND: Biomaterial research has made available a biologically derived fully resorbable poly-4-hydroxybutyrate (P4HB) mesh for use in ventral and incisional hernia repair (VIHR). This study evaluates outcomes of patients undergoing VIHR with P4HB mesh. METHODS: An IRB-approved prospective pilot study was conducted to assess clinical and quality of life (QOL) outcomes for patients undergoing VIHR with P4HB mesh. Perioperative characteristics were defined. Clinical outcomes, employment status, QOL using 12-item short form survey (SF-12), and pain assessments were followed for 24 months postoperatively...
September 15, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28913627/everolimus-eluting-bioresorbable-vascular-scaffold-in-daily-clinical-practice-a%C3%A2-single-centre-experience
#4
W S Remkes, R S Hermanides, M W Kennedy, E Fabris, E Kaplan, J P Ottervanger, A W J van 't Hof, E Kedhi
BACKGROUND: Recent evidence has raised concerns regarding the safety of the everolimus-eluting bioresorbable vascular scaffold (E-BVS) (Absorb, Abbott Vascular, Santa Clara, CA, USA). Following these data, the use of this device has diminished in the Netherlands; however, daily practice data are limited. Therefore we studied the incidence of safety and efficacy outcomes with this device in daily clinical practice in a single large tertiary centre in the Netherlands. METHODS: All E‑BVS treated patients were included in this analysis...
September 14, 2017: Netherlands Heart Journal
https://www.readbyqxmd.com/read/28903475/non-newtonian-pulsatile-shear-stress-assessment-a-method-to-differentiate-bioresorbable-scaffold-platforms
#5
Erhan Tenekecioglu, Ryo Torii, Christos V Bourantas, Rasha Al-Lamee, Patrick W Serruys
No abstract text is available yet for this article.
September 1, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28899664/implant-for-autologous-soft-tissue-reconstruction-using-an-adipose-derived-stem-cell-colonized-alginate-scaffold
#6
Tobias Hirsch, Christine Laemmle, Bjoern Behr, Marcus Lehnhardt, Frank Jacobsen, Dirk Hoefer, Maximilian Kueckelhaus
BACKGROUND: Adipose-derived stem cells represent an interesting option for soft tissue replacement as they are easy to procure and can generate their own blood supply through the production of angiogenic factors. We seeded adipose-derived stem cells on a bioresorbable, biocompatible polymer alginate scaffold to generate autologous soft tissue constructs for repair. MATERIALS AND METHODS: We built and optimized an alginate scaffold and tested its biocompatibility using the MTT assay and its hydration capacity...
August 16, 2017: Journal of Plastic, Reconstructive & Aesthetic Surgery: JPRAS
https://www.readbyqxmd.com/read/28898243/neoatherosclerosis-development-following-bioresorbable-vascular-scaffold-implantation-in-diabetic-and-non-diabetic-swine
#7
Nienke S van Ditzhuijzen, Mie Kurata, Mieke van den Heuvel, Oana Sorop, Richard W B van Duin, Ilona Krabbendam-Peters, Jurgen Ligthart, Karen Witberg, Magdalena Murawska, Brett Bouma, Martin Villiger, Hector M Garcia-Garcia, Patrick W Serruys, Felix Zijlstra, Gijs van Soest, Dirk-Jan Duncker, Evelyn Regar, Heleen M M van Beusekom
BACKGROUND: DM remains a risk factor for poor outcome after stent-implantation, but little is known if and how DM affects the vascular response to BVS. AIM: The aim of our study was to examine coronary responses to bioresorbable vascular scaffolds (BVS) in swine with and without diabetes mellitus fed a 'fast-food' diet (FF-DM and FF-NDM, respectively) by sequential optical coherence tomography (OCT)-imaging and histology. METHODS: Fifteen male swine were evaluated...
2017: PloS One
https://www.readbyqxmd.com/read/28894605/optical-coherence-tomography-guidance-during-bioresorbable-vascular-scaffold-implantation
#8
REVIEW
Gioel Gabrio Secco, Monica Verdoia, Gianfranco Pistis, Giuseppe De Luca, Matteo Vercellino, Andrea Audo, Rosario Parisi, Maurizio Reale, Giorgio Ballestrero, Paolo Nicola Marino, Carlo Di Mario
Bioresorbable vascular scaffold (BRS) represent a revolutionary concept in interventional cardiology. After initial enthusiasm, recent real world registries, including patients with increasing lesion complexity, reported not trivial rates of scaffold thrombosis (ScT). The importance of correct patients selection as well as technical aspects during BRS implantation procedures has been highlighted in several studies suggesting that the high rate of ScT might be related to uncorrected patients/lesions selection together with underutilization of intracoronary imaging guidance leading to suboptimal BRS implantation...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894604/new-generation-bioresorbable-scaffold-technologies-an-update-on-novel-devices-and-clinical-results
#9
REVIEW
Damiano Regazzoli, Pier Pasquale Leone, Antonio Colombo, Azeem Latib
Bioresorbable scaffolds (BRS) represent a novel horizon in interventional cardiology and may lead to some potential long-term advantages including the restoration of vasomotion, positive remodeling and a reduced incidence of late and very-late scaffold thrombosis (ScT). This technology, introduced to overcome limitations of current metallic drug-eluting stents (DES), is constantly and rapidly evolving with many companies working on bioresorbable devices. The aim of this review is to present an update on the most promising scaffolds that are under development...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894603/are-acute-coronary-syndromes-an-ideal-scenario-for-bioresorbable-vascular-scaffold-implantation
#10
REVIEW
Elisabetta Moscarella, Alfonso Ielasi, Maria Carmen De Angelis, Fortunato Scotto di Uccio, Enrico Cerrato, Roberta De Rosa, Gianluca Campo, Attilio Varricchio
Bioresorbable vascular scaffolds (BRS) represent the latest innovation in the field of interventional cardiology. BRS have recently been introduced in routine clinical practice and their use has progressively extended in everyday clinical practice. The BRS use appears theoretically attractive in patients presenting with acute coronary syndromes (ACS) as they are generally young with long life expectancy, thus possibly benefiting more of the so-called vascular reparative therapy. Furthermore, "culprit" lesions are usually softer and more easily expandable by current BRS compared to stable chronic lesions...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894602/methods-to-assess-bioresorbable-vascular-scaffold-devices-behaviour-after-implantation
#11
REVIEW
Alberto Pernigotti, Elisabetta Moscarella, Giosafat Spitaleri, Claudia Scardino, Kohki Ishida, Salvatore Brugaletta
Bioresorbable vascular scaffolds (BRS) represent a novel approach for coronary revascularization offering several advantages as compared to current generation DES, potentially reducing rate of late adverse events and avoiding permanent vessel caging. Nevertheless, safety concerns have been raised for an increased risk of scaffold thrombosis (ScT) in both early and late phases, probably related to a suboptimal scaffold implantation. In this context, the use of different imaging methodologies has been strongly suggested in order to guarantee an optimal implantation...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894601/the-desolve-novolimus-bioresorbable-scaffold-from-bench-to-bedside
#12
REVIEW
Alessio Mattesini, Simone Bartolini, Carlotta Sorini Dini, Serafina Valente, Guido Parodi, Miroslava Stolcova, Francesco Meucci, Carlo Di Mario
The DESolve (Elixir Medical Corporation, Sunnyvale, California, USA) is a poly-L lactide-based polymer scaffold coated with the antiproliferative and anti-inflammatory drug novolimus. The scaffold biodegrades within one year with a complete resorption in two years and in vitro bench test have shown the ability to supply the necessary radial strength to support the vessel for the critical 3- to 4-month period after implant. The DESolve showed the unique self-correction property, which may reduce the incidence of minor malapposition after deployment...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894600/current-concepts-on-coronary-revascularization-using-brs-in-patients-with-diabetes-and-small-vessels-disease
#13
REVIEW
Giulia Masiero, Marco Mojoli, Daisuke Ueshima, Giuseppe Tarantini
Diabetes mellitus (DM) and small vessel (SV) disease are two major predictors of adverse outcome in patients treated by percutaneous coronary intervention (PCI), even when last generation metallic drug-eluting stents (DES) are used. Bioresorbable scaffold (BRS) technology has been recently developed to overcome the disadvantages of metallic DES due to their permanent struts. Through the resorption process, BRS may provide a vascular restoration that appears very attractive especially when distal or diffusely diseased coronary segments are involved, as in diabetic patients and SV disease...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894599/occurrence-and-management-of-bioresorbable-vascular-scaffold-failure-in-real-life-studies
#14
REVIEW
Bernardo Cortese, Mostafa Elwany
Bioresorbable vascular scaffold (BVS) has emerged as a new technology aiming at overcoming some drawbacks of the conventional metallic stent. In spite of the initial promising results, this technology stumbled upon numerous challenges, which were revealed in the real world studies. Thanks to real world trials and registries findings, our knowledge about the BVS has grown over time, thus we have understood on BVS behavior in various settings and formulated better implantation techniques. In this article, we will review the incidence of BVS failure in real world studies, its different etiologies and management strategies...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894598/mechanical-behavior-of-polymer-based-vs-metallic-based-bioresorbable-stents
#15
REVIEW
Hui Ying Ang, Ying Ying Huang, Soo Teik Lim, Philip Wong, Michael Joner, Nicolas Foin
Bioresorbable scaffolds (BRS) were developed to overcome the drawbacks of current metallic drug-eluting stents (DES), such as late in-stent restenosis and caging of the vessel permanently. The concept of the BRS is to provide transient support to the vessel during healing before being degraded and resorbed by the body, freeing the vessel and restoring vasomotion. The mechanical properties of the BRS are influenced by the choice of the material and processing methods. Due to insufficient radial strength of the bioresorbable material, BRS often required large strut profile as compared to conventional metallic DES...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894597/brs-implantation-in-long-lesions-requiring-device-overlapping-myth-or-reality
#16
REVIEW
Simone Biscaglia, Andrea Erriquez, Davide Bernucci, Giulia Bugani, Enrico Favaretto, Gianluca Campo
Dealing with bioresorbable vascular scaffolds (BVS) implantation in long lesions requiring device overlapping in this particular moment might seem a little provocative for several reasons. First, most studies testing BVS have focused on their safety and efficacy profile in simple patients with simple lesions. Second, ABSORB II did not meet its primary endpoint, while ABSORB III showed a higher rate of target vessel-myocardial infarction (TV-MI) at 2 years. Third, data on porcine model showed that overlapping zone has delayed but greater neointimal proliferation with consequent higher risk for scaffold thrombosis in the short-term and of in-scaffold restenosis in the long-term...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894596/magmaris-a-new-generation-metallic-sirolimus-eluting-fully-bioresorbable-scaffold-present-status-and-future-perspectives
#17
REVIEW
Claudio Rapetto, Massimo Leoncini
Drug-eluting stents (DES) have reached a high safety and efficacy profile, becoming the best option for percutaneous coronary interventions (PCI) based revascularization. However, despite their optimal performance, a few concerns remain regarding their use, mainly due to permanent caging of the vessels and its consequences, first of all late stent thrombosis (ST). Bioresorbable scaffolds (BRS) aim to overcome these issues. The results achieved in randomized controlled trials (RCT) by the first generation of poly-L-lactic acid (PLLA) based scaffolds were promising at 1 year, but the first long term reports (albeit flawed by non-optimal implantation technique) have been disappointing, showing, for instance, an increased risk of ST and target vessel myocardial infarction (TV-MI)...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894595/the-impact-of-the-3-year-absorb-ii-trial-results-on-my-clinical-practice-an-italian-survey
#18
Matteo Serenelli, Simone Biscaglia, Elisabetta Tonet, Arnaldo Poli, Elisa Nicolini, Alfonso Ielasi, Andrea Erriquez, Gianluca Campo
BACKGROUND: To evaluate how the 3-year results from the "A clinical evaluation to compare the safety, efficacy and performance of ABSORB everolimus eluting bioresorbable vascular scaffold (BVS) system against XIENCE everolimus eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions" (ABSORB II) trial have influenced clinical practice among Italian interventional cardiologists. METHODS: We performed a survey among 95 interventional cardiologists sending a brief questionnaire by electronic mail...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894594/effectiveness-and-safety-of-the-absorb-bioresorbable-vascular-scaffold-for-the-treatment-of-coronary-artery-disease-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#19
Rita Pavasini, Matteo Serenelli, Francesco Gallo, Giulia Bugani, Salvatore Geraci, Paolo Vicinelli, Gianluca Campo
BACKGROUND: In the last years bioresorbable vascular scaffold (BVS) become a new therapeutic option for interventional cardiologists, with the advantage of a scaffold inducing a possible vessel wall restoration. Nevertheless, several trials tried to prove the safety and efficacy profile of scaffolds, but with conflicting results. METHODS: A systematic review and meta-analysis was performed. The search was carried out in PubMed, Google Scholar, Biomed Central and Cochrane Library between January and March 2017...
August 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28894593/bioresorbable-coronary-scaffolds-in-2017
#20
Alfonso Ielasi, Gianluca Campo
No abstract text is available yet for this article.
August 2017: Journal of Thoracic Disease
keyword
keyword
97648
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"